- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML
December 7th 2025, 8:06pm
ASH Annual Meeting and Exposition
The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.
Blinatumomab Plus Ponatinib Shows Survival Advantage Over Chemo/TKI Regimen in Ph+ ALL
December 7th 2025, 7:10pm
ASH Annual Meeting and Exposition
Initial results from the phase 3 GIMEMA ALL2830 trial support the use of this chemotherapy-free approach as a new SOC for adult Ph-positive ALL.
Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML
December 7th 2025, 6:13pm
ASH Annual Meeting and Exposition
Decitabine/cedazuridine plus venetoclax produced a 91% response rate and 30-month median OS in high-risk MDS/CMML.
Zanubrutinib Demonstrates Long-Term Efficacy, Safety in Relapsed/Refractory CLL/SLL
December 7th 2025, 5:35pm
ASH Annual Meeting and Exposition
Zanubrutinib displayed long-term PFS and responses in patients with relapsed/refractory CLL/SLL.
Pirtobrutinib Matches Ibrutinib in ORR, Shows Potential PFS Edge in BTK Inhibitor–Naive CLL/SLL
December 7th 2025, 5:34pm
ASH Annual Meeting and Exposition
Pirtobrutinib yeilds superior overall response rates and promising progression-free survival compared to ibrutinib in chronic lymphocytic leukemia.
Epcoritamab Plus Rituximab and Lenalidomide Improves PFS in Pretreated Follicular Lymphoma
December 7th 2025, 4:15pm
ASH Annual Meeting and Exposition
The addition of epcoritamab to lenalidomide and rituximab improved PFS and ORR vs the combination alone in relapsed/refractory follicular lymphoma.
Gintemetostat Shows Early Activity and Manageable Safety in Triple-Class Refractory Multiple Myeloma
December 7th 2025, 2:57pm
ASH Annual Meeting and Exposition
Gintemetostat demonstrates efficacy and safety in heavily pretreated multiple myeloma patients, paving the way for future combination therapies.
Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL
December 7th 2025, 2:55am
ASH Annual Meeting and Exposition
Hannah Goulart, MD, discusses the use of first-line blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.
Epcoritamab Plus R-mini-CHOP May Aid in Treatment of Elderly Patients with First-Line DLBCL
December 7th 2025, 2:52am
ASH Annual Meeting and Exposition
Epcoritamab plus R-mini-CHOP delivered deep responses with manageable safety in elderly, high-risk patients with newly diagnosed DLBCL.
Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML
December 7th 2025, 2:45am
ASH Annual Meeting and Exposition
Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.
Real-World Data Suggest ctDNA Status More Accurately Captures EFS Outcomes Than PET-CT
December 6th 2025, 11:34pm
ASH Annual Meeting and Exposition
ctDNA at end of treatment strongly predicted outcomes across lymphoma subtypes, outperforming imaging and supporting its role in personalized disease monitoring.
Axatilimab Dosing Shift Shows Feasibility in cGVHD
December 6th 2025, 10:10pm
ASH Annual Meeting and Exposition
The AGAVE-201 trial showed successful transition from axatilimab 0.3 mg/kg biweekly to 0.6 mg/kg monthly in cGVHD.
Odronextamab Plus CHOP Produces Deep, Potentially Durable Responses in Previously Untreated DLBCL
December 6th 2025, 9:42pm
ASH Annual Meeting and Exposition
Early phase 3 data showed signals of efficacy with the addition of odronextamab to CHOP in patients with previously untreated DLBCL and high-risk features.
Rusfertide Continues to Show Strong Results for Polycythemia Vera
December 6th 2025, 9:33pm
ASH Annual Meeting and Exposition
Rusfertide sustained hematocrit control and sharply reduced phlebotomy need through week 52 in PV, showing durable efficacy and a consistent safety profile.
KRd Demonstrates Superior PFS vs VRd in Newly Diagnosed Myeloma
December 6th 2025, 9:21pm
ASH Annual Meeting and Exposition
KRd improved PFS, deepened responses, and led to higher MRD negativity vs VRd in newly diagnosed multiple myeloma.
Long-Term CARTITUDE-4 Data Point to Potential Cure Fraction With Cilta-Cel in Standard-Risk R/R Myeloma
December 6th 2025, 8:13pm
ASH Annual Meeting and Exposition
In the CARTITUDE-4 trial, 80.5% of patients with standard-risk multiple myeloma were progression-free at 2.5 years after receiving cilta-cel.
Dr Scanlon on the Incidence, Management, and Physiologic Impact of IVC Tumor Thrombus in RCC
December 6th 2025, 8:08pm
Lorraine Scanlon, MD, discusses IVC tumor thrombus in RCC, its management, and how relieving venous congestion may improve renal function and guide future care.
Elranatamab Plus Iberdomide Shows Early Efficacy in R/R Multiple Myeloma
December 6th 2025, 8:00pm
ASH Annual Meeting and Exposition
Elranatamab plus iberdomide showed a 95.5% response rate in patients with BCMA-naive relapsed/refractory myeloma per early MagnetisMM-30 data.
Dr Li on Progression Risk in Low-Grade NMIBC and the Emerging Role of AI-Based Pathology Assessment
December 6th 2025, 7:46pm
Roger Li, MD, discusses progression risk in low-grade NMIBC and how AI-based pathology tools may improve identification of patients at risk for high-grade disease.
Survival in Induction Chemotherapy AML Studies May be Predictable by MRD
December 6th 2025, 7:15pm
ASH Annual Meeting and Exposition
Future AML study analyses may focus on measurable residual disease to predict OS through non-intensive modern treatment backbones.